Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Healthtrust
US Department of Justice
Cipla
Colorcon
Moodys
QuintilesIMS
Merck
Fuji

Generated: October 23, 2017

DrugPatentWatch Database Preview

Ticagrelor - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ticagrelor and what is the scope of ticagrelor patent protection?

Ticagrelor
is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are six patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Ticagrelor has two hundred and forty-six patent family members in forty-seven countries and twelve supplementary protection certificates in eleven countries.

There are nineteen drug master file entries for ticagrelor. Three suppliers are listed for this compound.

Summary for Generic Name: ticagrelor

US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: see list19
Suppliers / Packagers: see list3
Bulk Api Vendors: see list47
Clinical Trials: see list270
Patent Applications: see list181
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:ticagrelor at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-001Jul 20, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-001Jul 20, 2011RXYesYes► Subscribe► SubscribeYYY ► Subscribe
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-001Jul 20, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► SubscribeYYY ► Subscribe
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-001Jul 20, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-001Jul 20, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: ticagrelor

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,974,868 Compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ticagrelor

Country Document Number Estimated Expiration
Russian Federation2009104330► Subscribe
New Zealand574514► Subscribe
TaiwanI482772► Subscribe
Spain2207846► Subscribe
Russian Federation2317990► Subscribe
Japan2010501554► Subscribe
Portugal2056832► Subscribe
Japan5415383► Subscribe
Denmark1386921► Subscribe
Austria251161► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TICAGRELOR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0016France► SubscribePRODUCT NAME: TICAGRELOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/10/655/001 DU 20101203; REGISTRATION NO/DATE AT EEC: EU/1/10/655/001-006 DU 20101203
2011004Lithuania► SubscribePRODUCT NAME: TICAGRELORUM; REGISTRATION NO/DATE: EU/1/10/655/001 2010 12 03 EU/1/10/655/002 2010 12 03 EU/1/10/655/003 2010 12 03 EU/1/10/655/004 2010 12 03 EU/1/10/655/005 2010 12 03 EU/1/10/655/00 20101203
11/012Ireland► SubscribePRODUCT NAME: TICAGRELOR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/10/655/001-006 20101203
1135391/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
2011004,C1135391Lithuania► SubscribePRODUCT NAME: TICAGRELORUM; REGISTRATION NO/DATE: EU/1/10/655/001 2010 12 03 EU/1/10/655/002 2010 12 03 EU/1/10/655/003 2010 12 03 EU/1/10/655/004 2010 12 03 EU/1/10/655/005 2010 12 03 EU/1/10/655/00 20101203
819Luxembourg► Subscribe91819, EXPIRES: 20241202
2011 00013Denmark► Subscribe
2011100004Germany► SubscribePRODUCT NAME: TICAGRELOR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/655/001-006 20101203
90009-9Sweden► SubscribePRODUCT NAME: TICAGRELOR ELLER ETT FARMACEUTISKT ACCEPTABELT SALT DAERAV; REG. NO/DATE: EU/1/10/655/001-006 20101203
C/GB11/016United Kingdom► SubscribePRODUCT NAME: TICAGRELOR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/10/655/001 20101203; UK EU/1/10/655/002 20101203; UK EU/1/10/655/003 20101203; UK EU/1/10/655/004 20101203; UK EU/1/10/655/005 20101203; UK EU/1/10/655/006 20101203
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
McKinsey
US Army
Deloitte
AstraZeneca
Julphar
Teva
Covington
US Department of Justice
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot